Thermo Pays $3.5B for Phadia

Xconomy Boston — 

Waltham, MA-based Thermo Fisher Scientific (NASDAQ: TMO), a provider of products and services for labs, announced that it has acquired Sweden-based Phadia from the European private equity firm Cinven for about $3.5 billion in cash. The acquisition of Phadia, which provides allergy and autoimmunity diagnostic products, is expected to close fourth quarter 2011 and will likely be immediately accretive to Thermo’s adjusted earnings per share, the company said.

By posting a comment, you agree to our terms and conditions.

Comments are closed.